ChiCTR2300074345 版本V1.0 版本创建时间2023/08/04 08:52:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300074345 

最近更新日期:

Date of Last Refreshed on:

2023-08-04 08:50:40 

注册时间:

Date of Registration:

2023-08-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

含服达克罗宁胶浆对全身麻醉患者术后咽喉痛的影响

Public title:

Effect of oral dclonine mucilage on laryngopharyngeal pain after general anesthesia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

含服达克罗宁胶浆对全身麻醉患者术后咽喉痛的影响

Scientific title:

Effect of oral dclonine mucilage on laryngopharyngeal pain after general anesthesia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

翟明玉 

研究负责人:

谢言虎 

Applicant:

Zhai Mingyu 

Study leader:

Xie Yanhu 

申请注册联系人电话:

Applicant telephone:

+86 150 0560 9638

研究负责人电话:

Study leader's telephone:

+86 139 5601 3081

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zmynjl@126.com

研究负责人电子邮件:

Study leader's E-mail:

xyh200701@sina.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市政务区天鹅湖路1号安徽省立医院南区

研究负责人通讯地址:

安徽省合肥市政务区天鹅湖路1号安徽省立医院南区

Applicant address:

South District, Anhui Provincial Hospital, 1 Swan Lake Road, Hefei Municipal Administration District, Anhui Province

Study leader's address:

South District, Anhui Provincial Hospital, 1 Swan Lake Road, Hefei Municipal Administration District, Anhui Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国科学技术大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of University of Science and Technology of China

研究负责人所在单位:

中国科学技术大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of University of Science and Technology of China

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023KY伦审第016号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国科学技术大学附属第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First Affiliated Hospital of University of Science and Technology of China

伦理委员会批准日期:

Date of approved by ethic committee:

2023-02-16 00:00:00

伦理委员会联系人:

沈佐君

Contact Name of the ethic committee:

Shen zuojun

伦理委员会联系地址:

安徽省合肥市庐阳区庐江路17号

Contact Address of the ethic committee:

17 Lujiang Road, Luyang District, Hefei City, Anhui Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 6228 2931

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国科学技术大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of University of Science and Technology of China

研究实施负责(组长)单位地址:

安徽省合肥市政务区天鹅湖路1号安徽省立医院南区

Primary sponsor's address:

South District, Anhui Provincial Hospital, 1 Swan Lake Road, Hefei Municipal Administration District, Anhui Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽省

市(区县):

合肥市

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

中国科学技术大学附属第一医院

具体地址:

安徽省合肥市政务区天鹅湖路1号安徽省立医院南区

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China

Address:

South District, Anhui Provincial Hospital, 1 Swan Lake Road, Hefei Municipal Administration District, Anhui Province

经费或物资来源:

自筹

Source(s) of funding:

self-financing

Target disease:

Sore throat

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

术后咽喉痛(Postoperative Sore Throat,POST)是全身麻醉气道管理后最常见的并发症之一,POST除增加患者不适及降低麻醉恢复质量外,还将影响患者的住院满意度,延长患者住院时间。如何预防全身麻醉患者POST的发生,已经成为临床上一个亟待解决的问题。局麻药涂抹气管导管和喉罩可以预防POST的发生,盐酸达克罗宁胶浆是一种新型局部麻醉药,其可有效抑制气管插管时的应激反应,在粘膜麻醉方面,盐酸达克罗宁胶浆比丁卡因和利多卡因更有效,在清醒插管患者中,含服盐酸达克罗宁胶浆使用步骤简单,比丁卡因喷雾剂具有更好的黏膜麻醉效果和插管条件。本研究目的在于观察在全身麻醉患者中,含服盐酸达克罗宁是否可以降低术后咽喉痛的发生和术后咽喉痛评分。  

Objectives of Study:

Postoperative Sore Throat (POST) is one of the most common complications after airway management under general anesthesia. POST not only increases patients' discomfort and reduces the quality of anesthesia recovery, but also affects patients' hospitalization satisfaction and prolongs the hospital stay. How to prevent POST in general anesthesia patients has become an urgent problem in clinic. The application of local anesthetics to tracheal tubes and laryngeal masks can prevent the occurrence of POST. Dclonine hydrochloride gel is a new type of local anesthetic, which can effectively inhibit the stress response during tracheal intubation. In terms of mucosal anesthesia, Dclonine hydrochloride gel is more effective than tetracaine and lidocaine. Compared with tetracaine spray, it has better mucosal anesthetic effect and intubation conditions. The objective of this study was to observe whether the administration of dclonine hydrochloride can reduce the occurrence and score of postoperative sore throat in patients with general anesthesia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

气管插管或者喉罩的全身麻醉患者; ASA I-III级; 年龄 18-70岁; 预计机械通气时间小于等于4h。

Inclusion criteria

Patients under general anesthesia with tracheal intubation or laryngeal mask; ASA Level I-III; Age 18-70 years old; The expected mechanical ventilation time is less than or equal to 4h.

排除标准:

有精神病史或长期应用精神类药物者;对局部麻醉药过敏者; 合并有心( NYHA心功能分级 III级及以上者)、肝 (Child分级C级)、肾(需维持性透析者)等重要系统器官疾病失代偿者; 慢性呼吸系统疾病、哮喘病史、慢性咽炎病史、咽喉疼痛或声音嘶哑患者; 头颈部手术、口咽部手术和心脏手术的患者; 气道损伤或受压,评估为困难气道的患者; 既往行食管癌或者胃癌根治术者;有咽喉部结构病变或手术史; 拒绝参与本项研究或者正在参与其他研究者。

Exclusion criteria:

People with a history of mental illness or long-term use of psychotropic drugs; Allergic to local anesthetics; Patients with decompensated heart (NYHA heart function grade III and above), liver (Child grade C), kidney (maintenance dialysis) and other vital system organ diseases; Patients with chronic respiratory disease, asthma history, chronic pharyngitis history, sore throat or hoarseness; Patients undergoing head and neck surgery, oropharyngeal surgery and heart surgery; Patients with airway injury or compression, assessed as having a difficult airway; Patients who have previously undergone radical surgery for esophageal or gastric cancer; Have a history of structural lesions or surgery in the throat; Declined to participate in the study or is participating in other researchers.

研究实施时间:

Study execute time:

From 2023-08-06 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-08-06 00:00:00 To 2024-12-31 00:00:00  

干预措施:

Interventions:

组别:

气管插管对照组

样本量:

1150

Group:

Con Group (TI)

Sample size:

干预措施:

气管插管全麻的患者,麻醉诱导前含服生理盐水

干预措施代码:

Intervention:

Patients with tracheal intubation and general anesthesia should take normal saline before anesthesia induction

Intervention code:

组别:

气管插管达克罗宁组

样本量:

1150

Group:

Dyc Group (TI)

Sample size:

干预措施:

气管插管全麻的患者,麻醉诱导前含服达克罗宁胶浆

干预措施代码:

Intervention:

In patients with tracheal intubation and general anesthesia, dclonine was administered before induction of anesthesia

Intervention code:

组别:

喉罩对照组

样本量:

1450

Group:

Con Group (LM)

Sample size:

干预措施:

喉罩全麻的患者,麻醉诱导前含服生理盐水

干预措施代码:

Intervention:

For patients with laryngeal mask anesthesia, normal saline should be administered before anesthesia induction

Intervention code:

组别:

喉罩达克罗宁组

样本量:

1450

Group:

Dyc Group (LM)

Sample size:

干预措施:

喉罩全麻的患者,麻醉诱导前含服达克罗宁胶浆

干预措施代码:

Intervention:

In patients with laryngeal mask anesthesia, dclonine paste was administered before anesthesia induction

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽省 

市(区县):

合肥市 

Country:

China 

Province:

Anhui 

City:

Hefei 

单位(医院):

中国科学技术大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽省 

市(区县):

合肥市 

Country:

China 

Province:

Anhui 

City:

Hefei 

单位(医院):

安徽中医药大学第一附属医院 

单位级别:

三级 

Institution
hospital:

The First Affiliated Hospital of Anhui University of Chinese Medicine

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

淮南市 

Country:

China 

Province:

Anhui 

City:

Huainan 

单位(医院):

淮南市第一人民医院 

单位级别:

三级 

Institution
hospital:

Huainan City first People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

蚌埠市 

Country:

China 

Province:

Anhui 

City:

Bengbu  

单位(医院):

蚌埠市第三人民医院 

单位级别:

三级 

Institution
hospital:

Bengbu Third People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

池州市 

Country:

China 

Province:

Anhui 

City:

Chizhou 

单位(医院):

池州市人民医院 

单位级别:

三级 

Institution
hospital:

Chizhou People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

肥西县 

Country:

China 

Province:

Anhui 

City:

 

单位(医院):

肥西县人民医院 

单位级别:

二级 

Institution
hospital:

Feixi County People's Hospital

Level of the institution:

Secondary

国家:

中国

省(直辖市):

安徽省 

市(区县):

阜阳市 

Country:

China 

Province:

Anhui 

City:

Fuyang 

单位(医院):

阜阳市第二人民医院 

单位级别:

三级 

Institution
hospital:

Fuyang Second People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

合肥市 

Country:

China 

Province:

Anhui 

City:

Hefei 

单位(医院):

合肥市第三人民医院 

单位级别:

三级 

Institution
hospital:

Hefei Third People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

黄山市 

Country:

China 

Province:

Anhui 

City:

Huangshan 

单位(医院):

黄山市人民医院 

单位级别:

三级 

Institution
hospital:

Huangshan People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

利辛县 

Country:

China 

Province:

Anhui 

City:

Lixing 

单位(医院):

利辛县人民医院 

单位级别:

三级 

Institution
hospital:

Lixing County People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

临泉县 

Country:

China 

Province:

Anhui 

City:

Linquan 

单位(医院):

临泉县人民医院 

单位级别:

三级 

Institution
hospital:

Linquan County People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

宿州市 

Country:

China 

Province:

Anhui 

City:

Suzhou 

单位(医院):

宿州市立医院 

单位级别:

三级 

Institution
hospital:

Suzhou Municipal Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

六安 

Country:

China 

Province:

Anhui 

City:

Liuan 

单位(医院):

皖西卫生职业学院附属医院 

单位级别:

三级 

Institution
hospital:

West Anhui Health Vocational College affiliated Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

芜湖 

Country:

China 

Province:

Anhui 

City:

Wuhu 

单位(医院):

皖南医学院第二附属医院 

单位级别:

三级 

Institution
hospital:

The Second Affiliated Hospital of Wannan Medical College

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

宣城市 

Country:

China 

Province:

Anhui 

City:

Xuancheng 

单位(医院):

宣城市人民医院 

单位级别:

三级 

Institution
hospital:

Xuancheng People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

安徽省 

市(区县):

颍上县 

Country:

China 

Province:

Anhui 

City:

Yingshang 

单位(医院):

颍上县人民医院 

单位级别:

二级 

Institution
hospital:

Yingshang County People's Hospital

Level of the institution:

Secondary

测量指标:

Outcomes:

指标中文名:

患者术后咽喉疼痛VAS评分

指标类型:

主要指标

Outcome:

VAS score of postoperative sore throat

Type:

Primary indicator

测量时间点:

拔管后30min、6h、24h和48h

测量方法:

Measure time point of outcome:

30min, 6h, 24h and 48h after extubation

Measure method:

指标中文名:

Prince-Henry 评分法进行咽痛分级

指标类型:

主要指标

Outcome:

Pharyngeal pain was graded by Prince-Henry score

Type:

Primary indicator

测量时间点:

拔管后30min、6h、24h和48h

测量方法:

Measure time point of outcome:

30min, 6h, 24h and 48h after extubation

Measure method:

指标中文名:

声音嘶哑的发生情况

指标类型:

次要指标

Outcome:

The occurrence of hoarseness

Type:

Secondary indicator

测量时间点:

30min、6h、24h48h

测量方法:

Measure time point of outcome:

30min, 6h, 24h and 48h after extubation

Measure method:

指标中文名:

心率,血压,脉氧

指标类型:

次要指标

Outcome:

HR,BP,SPO2

Type:

Secondary indicator

测量时间点:

基础状态,含服药物结束,麻醉诱导前,插管后即刻,插管后5min

测量方法:

Measure time point of outcome:

Basic state, end of drug administration, before anesthesia induction, immediately after intubation, 5 minutes after intubation

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

/

组织:

Sample Name:

/

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

翟明玉 使用SPSS采用随机数字表法

Randomization Procedure (please state who generates the random number sequence and by what method):

Zhai Mingyu uses SPSS to adopt the random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-04 08:50:40